Market capitalization | $696.08m |
Enterprise Value | $2.05b |
PER (TTM) P/E ratio | 9.92 |
EV/FCF (TTM) EV/FCF | 217.58 |
EV/Sales (TTM) EV/Sales | 1.81 |
P/S ratio (TTM) P/S ratio | 0.61 |
P/B ratio (TTM) P/B ratio | negative |
Dividend yield | 4.97% |
Last dividend (FY23) | $0.60 |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
4 Analysts have issued a Embecta forecast:
4 Analysts have issued a Embecta forecast:
Mar '24 |
+/-
%
|
||
Net Profit | 29 29 |
106%
106%
|
|
Depreciation and Amortization | 10 10 |
28%
28%
|
|
Stock Compensation | 6.50 6.50 |
12%
12%
|
|
Operating Cash Flow | 24 24 |
287%
287%
|
|
Investments | 3.40 3.40 |
41%
41%
|
|
Dividend Paid | 8.60 8.60 |
50%
50%
|
|
Free Cash Flow | 21 21 |
211%
211%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Head office | United States |
CEO | Devdatt Kurdikar |
Employees | 2,200 |
Founded | 1924 |
Website | www.embecta.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.